Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PEN logo PEN
Upturn stock ratingUpturn stock rating
PEN logo

Penumbra Inc (PEN)

Upturn stock ratingUpturn stock rating
$271.68
Last Close (24-hour delay)
Profit since last BUY0%
upturn advisory
Consider higher Upturn Star rating
BUY since 1 day
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: PEN (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

18 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $310.88

1 Year Target Price $310.88

Analysts Price Target For last 52 week
$310.88 Target price
52w Low $184.8
Current$271.68
52w High $310

Analysis of Past Performance

Type Stock
Historic Profit 4.32%
Avg. Invested days 45
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 10.60B USD
Price to earnings Ratio 71.87
1Y Target Price 310.88
Price to earnings Ratio 71.87
1Y Target Price 310.88
Volume (30-day avg) 18
Beta 0.4
52 Weeks Range 184.80 - 310.00
Updated Date 08/29/2025
52 Weeks Range 184.80 - 310.00
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) 3.78

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 11.54%
Operating Margin (TTM) 12.03%

Management Effectiveness

Return on Assets (TTM) 6.2%
Return on Equity (TTM) 12.03%

Valuation

Trailing PE 71.87
Forward PE 76.92
Enterprise Value 10391249366
Price to Sales(TTM) 8.28
Enterprise Value 10391249366
Price to Sales(TTM) 8.28
Enterprise Value to Revenue 8.12
Enterprise Value to EBITDA 53.66
Shares Outstanding 38999100
Shares Floating 37816675
Shares Outstanding 38999100
Shares Floating 37816675
Percent Insiders 3.63
Percent Institutions 93.28

ai summary icon Upturn AI SWOT

Penumbra Inc

stock logo

Company Overview

overview logo History and Background

Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California. The company is a global healthcare company focused on innovative therapies. Initially, it focused on stroke treatment but has since expanded into other vascular and neurovascular areas. Major milestones include FDA approvals for key products and significant growth in revenue and market share.

business area logo Core Business Areas

  • Vascular: This segment focuses on products for treating peripheral vascular and venous diseases, including aspiration systems, catheters, and thrombectomy devices.
  • Neurovascular: This segment offers products for treating neurovascular diseases, such as stroke and aneurysms, including aspiration systems, coils, and access devices.

leadership logo Leadership and Structure

Adam Elsesser is the Chairman and CEO. The company operates with a functional organizational structure with departments specializing in R&D, manufacturing, sales, and marketing.

Top Products and Market Share

overview logo Key Offerings

  • Penumbra System: An aspiration-based thrombectomy system for stroke treatment and peripheral vascular procedures. Market share information is variable depending on the geography and specific application, but it is a significant competitor to Medtronic, Stryker, and Johnson & Johnson in thrombectomy. Exact market share numbers are difficult to obtain without dedicated market research resources. Estimated revenue is substantial, but not publicly broken out separately from overall company revenue.
  • Indigo System: A percutaneous aspiration system used to remove thrombus and emboli from the peripheral vasculature. Competitors include Boston Scientific, Philips, and Medtronic. Market share information is variable depending on the geography and specific application. Estimated revenue is substantial, but not publicly broken out separately from overall company revenue.

Market Dynamics

industry overview logo Industry Overview

The medical device industry is characterized by high regulation, technological innovation, and increasing demand for minimally invasive procedures. Growth is driven by an aging population and advancements in medical technology.

Positioning

Penumbra is a key player in the interventional therapies market, specializing in neurovascular and vascular treatments. Its competitive advantage lies in its innovative product designs and focus on aspiration-based thrombectomy.

Total Addressable Market (TAM)

The total addressable market for neurovascular and vascular medical devices is estimated to be in the tens of billions of dollars globally. Penumbra is well-positioned to capture a significant portion of this TAM with its portfolio of innovative products and strong market presence.

Upturn SWOT Analysis

Strengths

  • Innovative Product Portfolio
  • Strong Brand Recognition
  • Focus on Aspiration Technology
  • Established Sales and Distribution Network
  • Experienced Leadership Team

Weaknesses

  • Product Recalls Impacting Reputation
  • Reliance on a Limited Number of Key Products
  • Exposure to Product Liability Claims
  • Dependence on regulatory approvals
  • Limited geographic diversification

Opportunities

  • Expanding Product Applications
  • Geographic Expansion into Emerging Markets
  • Strategic Acquisitions and Partnerships
  • Development of new technologies
  • Increase adoption in new procedures

Threats

  • Intense Competition
  • Regulatory Changes and Scrutiny
  • Product Liability Litigation
  • Economic Downturns Affecting Healthcare Spending
  • Changes in reimbursement policies

Competitors and Market Share

competitor logo Key Competitors

  • MDT
  • STRY
  • BSX
  • JNJ

Competitive Landscape

Penumbra's competitive advantage is based on its innovative aspiration technology, which it leverages to compete with larger, more diversified medical device companies. It faces challenges in terms of resources and product breadth.

Major Acquisitions

Mederis AG

  • Year: 2016
  • Acquisition Price (USD millions): 52
  • Strategic Rationale: Expanded Penumbra's neurovascular portfolio with innovative access technology.

Growth Trajectory and Initiatives

Historical Growth: Penumbra has historically demonstrated significant revenue growth, driven by product adoption and market expansion.

Future Projections: Analyst estimates vary, but generally project continued revenue growth in the coming years, based on new product launches and market penetration.

Recent Initiatives: Recent initiatives include expanding sales force, launching new products, and increasing R&D investment.

Summary

Penumbra is a growth-oriented medical device company with a focus on innovative neurovascular and vascular therapies. It has a strong product portfolio and market position, but faces challenges including product recalls and intense competition. The company's growth trajectory is dependent on successful product launches and expansion into new markets. Penumbra should carefully manage its product quality and regulatory risks.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings (10-K, 10-Q), Press Releases, Analyst Reports, Industry News

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual risk tolerance and due diligence. Market share data is estimated and may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Penumbra Inc

Exchange NYSE
Headquaters Alameda, CA, United States
IPO Launch date 2015-09-18
Co-Founder, Chairman, President & CEO Mr. Adam Elsesser J.D.
Sector Healthcare
Industry Medical Devices
Full time employees 4500
Full time employees 4500

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, and aspiration pump under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as detachable coils to treat patients with a wide range of neurovascular lesions under the Penumbra SMART COIL and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.